
WHAT IS CLAIMED:


1. A modified oligonucleotide according to the following chemical structure:



(SEQ ID NO: 2865), or a salt thereof.

2. The modified oligonucleotide of claim 1, which is the sodium salt or the potassium salt.

3. A modified oligonucleotide according to the following chemical structure:



(SEQ ID NO: 2865).

4. An oligomeric compound comprising a modified oligonucleotide according to the following chemical notation:

$A_{ks}A_{ds}G_{ds}T_{ds}G_{ds}T_{ds}A_{ds}T_{ds}G_{ds}T_{ds}{}^{m}C_{ds}A_{ks}G_{es}A_{ks}A_{es}G_{k}$ (SEQ ID NO: 2865);

$A_{ks}T_{ks}T_{ks}A_{ds}G_{ds}A_{ds}G_{ds}T_{ds}A_{ds}T_{ds}G_{ds}T_{ds}G_{ds}G_{ks}{}^{m}C_{ks}A_{k}$ (SEQ ID NO: 810);

$G_{ks}T_{ks}A_{ks}A_{ds}T_{ds}A_{ds}T_{ds}T_{ds}G_{ds}{}^{m}C_{ds}A_{ds}A_{ds}T_{ds}{}^{m}C_{ks}T_{ks}G_{k}$ (SEQ ID NO: 1404);

$T_{ks}T_{ks}A_{ks}A_{ds}A_{ys}G_{ds}T_{ds}G_{ds}T_{ds}A_{ds}T_{ds}G_{ds}T_{ds}{}^{m}C_{ks}A_{ks}G_{k}$ (SEQ ID NO: 2868);

$A_{ks}G_{ds}T_{ds}G_{ds}T_{ds}A_{ds}T_{ds}G_{ds}T_{ds}{}^{m}C_{ds}A_{ds}G_{ks}A_{es}A_{ks}G_{es}A_{k}$ (SEQ ID NO: 2864);

$G_{ks}T_{ks}A_{ks}A_{ds}T_{ds}A_{ds}T_{ds}T_{ds}G_{ds}{}^{m}C_{ds}A_{ds}A_{ds}T_{ks}{}^{m}C_{ks}T_{ks}G_{e}$ (SEQ ID NO: 1404);

$^{m}C_{ks}T_{ks}A_{ks}A_{ds}G_{ds}T_{ds}A_{ds}A_{ds}G_{ds}G_{ds}T_{ds}T_{ds}T_{ks}{}^{m}C_{ks}{}^{m}C_{ks}{}^{m}C_{e}$ (SEQ ID NO: 1101);

$T_{ks}A_{es}T_{ks}T_{ds}A_{ds}G_{ds}A_{ds}G_{ds}T_{ds}A_{ds}T_{ds}G_{ds}T_{es}G_{es}G_{ks}{}^{m}C_{k}$ (SEQ ID NO: 2812);

$^{m}C_{ks}A_{ks}{}^{m}C_{ds}T_{ds}T_{ds}T_{ds}T_{ds}A_{ds}{}^{m}C_{ds}A_{ds}T_{ds}T_{ks}A_{es}G_{ks}G_{es}A_{k}$ (SEQ ID NO: 1200); or

$T_{ks}G_{ks}T_{ds}A_{ds}T_{ds}G_{ds}T_{ds}{}^{m}C_{ds}A_{ds}G_{ds}A_{ds}A_{ks}G_{es}A_{ks}G_{es}T_{k}$ (SEQ ID NO: 2863);

or a salt thereof,

wherein:

A = an adenine nucleobase,

^{m}C = a 5-methyl cytosine nucleobase,

G = a guanine nucleobase,

T = a thymine nucleobase,

e = a 2'-O$(CH_2)_2$-OCH_3 furanosyl sugar moiety,

k = a cEt modified sugar moiety

d = a 2'-deoxyribose sugar moiety

s = a phosphorothioate internucleoside linkage, and

o = a phosphodiester internucleoside linkage.

5. A population of modified oligonucleotides of any of claims 1-3 or a population of oligomeric compounds of claim 4, wherein all of the phosphorothioate internucleoside linkages of the modified oligonucleotide are stereorandom.

6. A combination comprising a modified oligonucleotide of any of claims 1-3, an oligomeric compound of claim 4, or a population of modified oligonucleotides of claim 5, and a secondary agent.

7. The combination of claim 6, wherein the secondar agent is a CDK4/6 inhibitor.

8. The combination of claim 7, wherein the CDK4/6 inhibitor is palbociclib, ribociclic, or abemaciclib.

9. The combination of claim 6, wherein the secondary agent is an EGFR inhibitor.

10. The combination of claim 9, wherein the EGFR inhibitor is cetuximab, necitumumab, panitumumab, vandetanib, dacomitinib, neratinib, osimertinib, gefitinib, lapatinib, or erlotinib.

11. The combination of claim 6, wherein the secondary agent is a kinase inhibitor.

12. The combination of claim 11, wherein the kinase inhibitor is sorafenib, regorafenib, or carbozantinib.

13. A pharmaceutical composition comprising a modified oligonucleotide of any of claims 1-3, an oligomeric compound of claim 4, or a population of modified oligonucleotides of claim 5, and a pharmaceutically acceptable diluent.

14. The pharmaceutical composition of claim 13, wherein the pharmaceutically acceptable diluent is water or PBS.

15. The pharmaceutical composition of claim 14, wherein the pharmaceutical composition consists essentially of the modified oligonucleotide or oligomeric compound and water or PBS.

16. The pharmaceutical composition of claim 14, wherein the pharmaceutical composition consists essentially of the population of modified oligonucleotides or oligomeric compounds and water or PBS.

17. The use of a therapeutically effective amount of a modified oligonucleotide of any of claims 1-3, an oligomeric compound of claim 4, a population of modified oligonucleotides of claim 5, or a pharmaceutical composition of any of claims 13-16, for the manufacture of a medicament for treating a disease associated with YAP1, wherein the medicament is to be administered to a subject having a disease associated with YAP1, thereby treating the disease associated with YAP1.

18. The use of a therapeutically effective amount of a modified oligonucleotide of any of claims 1-3, an oligomeric compound of claim 4, a population of modified oligonucleotides of claim 5, or a pharmaceutical composition of any of claims 13-16, for the manufacture of a medicament for treating or ameliorating cancer in an individual, wherein the medicament is to be administered, thereby treating or ameliorating the cancer.

19. The use of claim 18, wherein the cancer is hepatocellular carcinoma (HCC), head and neck squamous cell carcinoma (HNSCC), head and neck cancer, pharynx carcinoma, laryngeal squamous cell carcinoma, oral tongue squamous cell carcinoma (OTSCC), squamous cell carcinoma (SCC), sarcomas (e.g. epitheloid, rhabdoid and synovial), esophageal cancer, gastric cancer, ovarian cancer, pancreatic cancer, tumors with mutations in SWI/SNF complex, lung cancer, non-small cell lung carcinoma (NSCLC), small-cell lung carcinoma (SCLC), gastrointestinal cancer, large intestinal cancer, small intestinal cancer, stomach cancer, colon cancer, colorectal cancer, bladder cancer, liver cancer, biliary tract cancer, urothelial cancer, breast cancer, triple-negative breast cancer (TNBC), endometrial cancer, cervical cancer, prostate cancer, mesothelioma, chordoma, renal cancer, renal cell carcinoma (RCC), brain cancer, neuroblastoma, glioblastoma, skin cancer, melanoma, basal cell carcinoma, merkel cell carcinoma, blood cancer, hematopoetic cancer, myeloma, multiple myeloma (MM), B cell malignancies, lymphoma, B cell lymphoma, Hodgkin lymphoma, T cell lymphoma, leukemia, or acute lymphocytic leukemia (ALL), a cancer having a mutant FAT1 gene, a cancer having a homozygous FAT1 gene mutation, or a cancer having a heterozygous FAT1 gene mutation, a squamous cell carcinoma (SCC) having a mutant FAT1 gene, a head and neck squamous cell carcinoma (HNSCC) having a mutant FAT1 gene, an oral tongue squamous cell carcinoma (OTSCC) having a mutant FAT1 gene, a pharynx carcinoma having a mutant FAT1 gene, or a laryngeal squamous cell carcinoma having a mutant FAT1 gene.

20. The use of a modified oligonucleotide of any of claims 1-3, an oligomeric compound of claim 4, a population of modified oligonucleotides of claim 5, or a pharmaceutical composition of any of claims 13-16, for the manufacture of a medicament for inhibiting expression of YAP1 in a cell,

wherein the inhibiting comprises contacting the cell with said modified oligonucleotide, oligomeric compound, population of modified oligonucleotides, or pharmaceutical composition, thereby inhibiting expression of YAP1 in the cell.

21. The use of claim 20, wherein the cell is a cancer cell.

22. The use of any of claims 17-19, wherein the subject is human.

23. The use of claim 20 or claim 21, wherein the cell is a human cell.

24. The use of claims 17-23, further comprising administering a secondary agent.

25. The use of claim 24, wherein the secondary agent is a CDK4/6 inhibitor.

26. The use of claim 25, wherein the CDK4/6 inhibitor is palbociclib, ribociclib, or abemaciclib.

27. The use of claim 24, wherein the secondary agent is an EGFR inhibitor.

28. The use of claim 27, wherein the EGFR inhibitor is cetuximab, necitumumab, panitumumab, vandetanib, dacomitinib, neratinib, osimertinib, gefitinib, lapatinib, or erlotinib.

29. The use of claim 24, wherein the secondary agent is a kinase inhibitor.

30. The use of claim 29, wherein the kinase inhibitor is sorafenib, regorafenib, or carbozantinib.